news

Our latest
Press Releases & Updates

Latest press releases

RetinAI’s technology accelerated large-scale analysis of fluid dynamics in a Real-World, neovascular Age-related Macular Degeneration (nAMD) national database

RetinAI is proud to have provided its CE-marked AI tools for fluid quantification to support the analysis in a large scale, multicenter, real-world national database of neovascular Age related Macular Degeneration (nAMD) patients. The results of the study, recently published in the British Journal of Ophthalmology, demonstrate that volumetric measures derived from AI-based segmentation of OCT volumes provide useful information for clinicians to consult their patients at diagnosis.

RetinAI launches Discovery CORE™: an AI-powered, collaborative platform to accelerate Clinical & Academic Research, & RWE analysis in ophthalmology

RetinAI is proud to launch Discovery CORE™ with AI for retinal fluid and layer segmentation. Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently, in real time, with their peers, on medical and imaging datasets. Automatically and in an instant, the software measures retinal fluid volumes and retinal layer thickness across OCT datasets. With built-in annotation tools and electronic case report forms, new data insights can also be collected across peer networks, keeping the information digitized, centralized and secure.

RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

RetinAI is a leader in clinical and imaging data management software and advanced analytics for Ophthalmology. The company’s platform technology and AI improve workflows in research, clinical studies and bring precision medicine applications to pharma, clinical research organizations (CROs) and clinicians.

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

RetinAI, a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, located in Boston, MA. This expansion will support further growth within the U.S. market, building upon existing collaborations with U.S.-based pharmaceutical companies and its partnership with Heidelberg Engineering to distribute RetinAI’s Disease AI Apps for research use in the U.S. The Boston office will be RetinAI’s second location, in addition to its Bern headquarters.

RetinAI on the Top100 Swiss Startups [SEPTEMBER’18]

This year RetinAI has been selected as one of the TOP 100 of Swiss Startups 2018! It’s a great recognition for the team. We are proud of the results we are achieving and we are extremely excited about the future ahead!

Welcome to the new RetinAI [SEPTEMBER'18]

There's nothing permanent except change - Heraclitus. We are incredibly pleased to announce our new logo at RetinAI! This new image reflects our values, strengths and willingness to connect the anatomical and digital worlds to provide a better healthcare for the patient.

Venture Leaders China 2018 [SEPTEMBER'18]

The 10-day business roadshow in China with VentureLab is only a week away! Get to know the Venture Leaders China team member Carlos Ciller, CEO & co-founder of RetinAI before the trip begins! Source: VentureLab.

AGEFI - RetinAI [JULY'18]

RetinAI is honoured to appear in the first page of AGEFI this 5th of July! Another opportunity to highlight how advanced machine learning and artificial intelligence are changing the world of ophthalmic care for the benefit of the patient and healthcare systems worldwide.

‍

Our latest
Press Releases & Updates

Latest press releases

RetinAI’s technology accelerated large-scale analysis of fluid dynamics in a Real-World, neovascular Age-related Macular Degeneration (nAMD) national database

RetinAI launches Discovery CORE™: an AI-powered, collaborative platform to accelerate Clinical & Academic Research, & RWE analysis in ophthalmology

RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

Latest updates

RetinAI on the Top100 Swiss Startups [SEPTEMBER’18]

Welcome to the new RetinAI [SEPTEMBER'18]

Venture Leaders China 2018 [SEPTEMBER'18]

AGEFI - RetinAI [JULY'18]

Contact us for more informations! We are happy to hear from you!

Sign Up And Receive Our Latest Promotions!

Our latest Press Releases & Updates

Latest press releases

RetinAI’s technology accelerated large-scale analysis of fluid dynamics in a Real-World, neovascular Age-related Macular Degeneration (nAMD) national database

RetinAI launches Discovery CORE™: an AI-powered, collaborative platform to accelerate Clinical & Academic Research, & RWE analysis in ophthalmology

RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

Latest updates

RetinAI on the Top100 Swiss Startups [SEPTEMBER’18]

Welcome to the new RetinAI [SEPTEMBER'18]

Venture Leaders China 2018 [SEPTEMBER'18]

AGEFI - RetinAI [JULY'18]

Contact us for more informations! We are happy to hear from you!

Our latest
Press Releases & Updates